Yali Fu
North University of China(CN)Genmab (Netherlands)(NL)Princeton Satellite Systems (United States)(US)La Roche College(US)
Publications by Year
Research Areas
Phagocytosis and Immune Regulation, HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Lung Cancer Treatments and Mutations, Neuroendocrine Tumor Research Advances
Most-Cited Works
- → Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden(2018)3,112 cited
- → Validation of the Female Sexual Distress Scale-Revised for Assessing Distress in Women with Hypoactive Sexual Desire Disorder(2007)723 cited
- → Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR -Mutant Lung Cancer with and without T790M Mutations(2014)354 cited
- → Activity of Afatinib/Cetuximab in Patients (PTS) with EGFR Mutant Non-Small Cell Lung Cancer (Nsclc) and Acquired Resistance (Ar) To EGFR Inhibitors(2012)49 cited
- → Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE(2014)35 cited
- → Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors(2018)